Oncternal Therapeutics (ONCT) - Financial and Strategic SWOT Analysis Review

Oncternal Therapeutics (ONCT) - Financial and Strategic SWOT Analysis Review

- provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

• Business description – A detailed description of the company’s operations and business divisions.
• Corporate strategy – Analyst’s summarization of the company’s business strategy.
• SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history – Progression of key events associated with the company.
• Major products and services – A list of major products, services and brands of the company.
• Key competitors – A list of key competitors to the company.
• Key employees – A list of the key executives of the company.
• Executive biographies – A brief summary of the executives’ employment history.
• Key operational heads – A list of personnel heading key departments/functions.
• Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
• Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
• Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Oncternal Therapeutics (Oncternal) is a clinical-stage biopharmaceutical company. It is focused on developing innovative oncology therapies to address significant unmet medical needs, particularly in prostate cancer. The company is evaluating zilovertamab, an investigational humanized monoclonal antibody that inhibits ROR1 function. It has been tested in a Phase 1/2 study (CIRM-0001) with ibrutinib for chronic lymphocytic leukemia (CLL), achieving progression-free survival in CLL patients with p53 mutations. Zilovertamab is currently being studied in a Phase 1b trial at UC San Diego, combining it with docetaxel for metastatic castration-resistant prostate cancer (mCRPC). Oncternal is headquartered in San Diego, California, the US.

Oncternal Therapeutics Key Recent Developments

Sep 12,2024: Oncternal Therapeutics Announces Termination of Its Clinical Studies and Exploration of Strategic Alternatives
Aug 08,2024: Oncternal Therapeutics Provides Business Update and Announces Second Quarter 2024 Financial Results
Mar 07,2024: Oncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Results
Oct 25,2023: Oncternal Therapeutics Adds Matthew Smith, M.D., Ph.D. to its Prostate Cancer Scientific Advisory Board

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note:Note: Some sections may be missing if data is unavailable for the company